New hope for advanced cervical cancer: drug combo trial shows promise

NCT ID NCT04982237

First seen Nov 19, 2025 · Last updated May 05, 2026 · Updated 22 times

Summary

This phase 3 trial tests whether adding the drug AK104 to standard chemotherapy (with or without bevacizumab) helps people with advanced cervical cancer live longer without their disease getting worse. About 445 women whose cancer has spread or returned and cannot be cured by surgery or radiation are taking part. The study compares the new combination to a placebo plus chemo to see if it improves survival and tumor shrinkage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Anhui Provincial Hospital

    Hefei, China

  • Fudan University Shanghai Cancer Center

    Shanghai, 200032, China

  • The Second Affiliated Hospital,Anhui Medical University

    Hefei, China

  • Women's Hospital School Of Medicine Zhejiang University

    Hangzhou, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

Conditions

Explore the condition pages connected to this study.